Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Neuronetics, Inc. is focused on designing, developing, and marketing products that...
Neuronetics, Inc. is focused on designing, deve...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...
SI-BONE is a medical device company that has pioneered a proprietary minimally inv...
SI-BONE is a medical device company that has pi...
Virtuoso Surgical, Inc. was born out of a collaborative research effort developing...
Virtuoso Surgical, Inc. was born out of a colla...
ConforMIS is a medical technology company that uses its proprietary iFitÂŽ Image-t...
ConforMIS is a medical technology company that ...
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular di...
GenMark Diagnostics (NASDAQ: GNMK) is a leading...
Inovio is bringing IMMUNO-INGENUITY⢠to life and is reshaping the future of trea...
Inovio is bringing IMMUNO-INGENUITY⢠to life ...
Join the National Investor Network and get the latest information with your interests in mind.